checkAd

     383  0 Kommentare Johnson & Johnson Division Attempts Final Appeal in Effort to Overturn Multiple USPTO Decisions Issued in DECN's Favor - Seite 2

    Lifescan from the outset had been eminently aware of the fragility of their legal patent position. Their only victorious path lay not in a court's decision, but through the protraction of the process in an attempt to force capitulation. Their plan combined restricting the sale of GenStrip through a preliminary injunction (subsequently overturned) with prolonged patent infringement litigation, thereby forcing Pharma Tech to burn precious capital in its legal defense.

    Mr. Berman continued, "We have long understood that J&J's ultimate goal was never to win a resounding legal victory in the prosecution of its indefensible legal position. The repeated court decisions have been consistently clear and extensively detailed. They have upheld Pharma Tech's legal right to manufacture and sell GenStrip while consistently maintaining that it's having done so has never, in any way, infringed on J&J/Lifescan's bellweather patent. We have repeatedly stated that position, the courts have consistently sustained it and Lifescan knows it. Their intent was never to beat us in court but to prevent us from selling the product while forcing us to allocate company resources for a legal defense of this spurious suit. However, it is important to note that, just as they have failed in court, they have abysmally failed in their strategy. We will continue the battle to its now inevitable and imminent conclusion, GenStrip will prevail, and Pharma Tech will expend any and all resources necessary to do so."

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Johnson & Johnson!
    Long
    132,67€
    Basispreis
    1,09
    Ask
    × 12,27
    Hebel
    Short
    155,91€
    Basispreis
    1,10
    Ask
    × 12,16
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Forward-Looking Statements:

    This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates," "will" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.

    For further information about the Pharma Tech GenStrip™ 50, please visit the company's Web Sites: http://www.decisiondiagnostics.com or http://www.pharmatechdirect.com or http://www.new-genstrip.com.

    GenStrip™ 50 test strips are a product of Pharma Tech Solutions, Inc., and are not manufactured, distributed, endorsed, or approved by nor associated with LifeScan, Inc. a Johnson & Johnson company, manufacturers and distributors of the OneTouch Ultra family of meters and OneTouch Ultra test strips.

    Contact:

    Decision Diagnostics Corp.
    Keith Berman
    (805) 446-2973
    info@decisiondiagnostics.com

    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte



    Verfasst von Marketwired
    Johnson & Johnson Division Attempts Final Appeal in Effort to Overturn Multiple USPTO Decisions Issued in DECN's Favor - Seite 2 LOS ANGELES, CA--(Marketwired - Mar 31, 2015) - Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip™ 50, the …

    Schreibe Deinen Kommentar

    Disclaimer